Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s hiring — we bring you the top stories that matter most. Stay informed with a curated selection of the latest news, delivered directly to your inbox weekly.
This week, the BioHealth Capital Region showed that innovation increasingly runs on partnership, with companies pairing up with academic labs, federal agencies, and each other to move science forward faster than any one player could alone.
From Frederick-based Stemora tapping UMD’s hydrogel expertise for its cartilage regeneration candidate to Emergent BioSolutions landing a $24 million BARDA modification for its anthrax vaccine, capital kept flowing toward programs with federal and academic backing. Meanwhile, ARPA-H committed up to $125 million across five teams to build an automated network for made-to-order genetic medicines, and a deep dive this week broke down five regulatory pressure points reshaping how biopharma quality teams operate in 2026.
TEDCO President Tammi Thomas offered her own view this week on how the organization has evolved from an early-stage funder into a broader partner for Maryland startups. On the talent side, Charlottesville’s Adovate deepened the region’s pipeline through a hands-on summer internship program with UVA, and BioBuzz’s own Career Catalyst series kicked back off, giving early-career professionals a weekly dose of real-world guidance to find their footing in the industry.
Financial
Tracking the capital moving through the BioHealth Capital Region — funding rounds, M&A activity, and investment trends shaping Maryland, DC, and Virginia’s life sciences companies.
Frederick’s Stemora Secures $100,000 MIPS Matching Grant to Fund UMD Cartilage Research Collaboration
Frederick-based Stemora has received a $100,000 matching MIPS grant to partner with UMD Professor Srinivasa Raghavan’s lab, engineering a controlled-release hydrogel to deliver STM-01, its lead cartilage regeneration candidate, in a precisely timed two-step profile. The award marks Stemora’s third disclosed 2026 funding win, following $330,000 in earlier support from TEDCO and the NSF, this time adding an academic collaborator directly into its formulation science. Read More >
Gaithersburg’s Emergent BioSolutions Lands $24 Million BARDA Modification for Its Anthrax Vaccine
Emergent BioSolutions has secured a roughly $24 million contract modification from BARDA for CYFENDUS, its FDA-approved anthrax vaccine, reinforcing domestic manufacturing and supply readiness for post-exposure prophylaxis. The award adds to a string of 2026 federal biodefense contract modifications for the company, including recent BioThrax, ACAM2000, and BAT awards, underscoring the government’s continued reliance on Emergent’s countermeasure portfolio. Read More >
Quoin Pharmaceuticals Secures Up to $50 Million to Advance Rare Disease Pipeline
Ashburn, VA-based Quoin Pharmaceuticals has closed a private placement that could raise up to $50 million, enough to fund the company into the second half of 2029 if accompanying warrants are fully exercised. The financing supports Quoin’s rare disease pipeline, led by QRX003 for Netherton Syndrome, which just reported positive interim trial data meeting its primary endpoint with statistical significance. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
Stefanie Trop Ph.D., will join the MCEDC team as new Vice President of Economic Competitiveness
MCEDC has named Dr. Stefanie Trop to the newly created role of Vice President of Economic Competitiveness, tasking her with expanding the organization’s research and business intelligence capabilities. Trop joins from the Maryland Department of Commerce, where she spent nearly five years as Director, Life Sciences, most recently leading the Maryland Life Sciences Advisory Board and co-founding the Maryland MedTech Summit. Read More >
Valerie Cella Joins AstraZeneca as a US Oncology Commercial Leadership Associate
Valerie Cella has joined AstraZeneca’s Commercial Leadership Development Program in Gaithersburg, taking on Enhertu tumor-agnostic marketing in her first year. A registered nurse turned healthcare strategist with an MBA from Duke’s Fuqua School of Business, Cella brings pediatric cardiac care experience and prior clinical marketing work at Edwards Lifesciences to her new role in oncology commercial strategy. Read More >
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
OncoC4 has welcomed Dr. Steve Chen, JD, PhD, General Counsel, bringing nearly two decades of legal and IP experience in biotech, most recently as General Counsel of both HiFiBiO Therapeutics and ENSEM Therapeutics. Chen will oversee corporate governance, IP strategy, and business development as the Rockville-based company advances its clinical pipeline and expands global operations. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across Maryland, DC, and Virginia’s life sciences and biotech employers.
Adovate Partners with CvilleBioHub, VEDP, and the University of Virginia to Develop Virginia’s Next Generation of Biotechnology Talent
Charlottesville-based Adovate has completed a summer internship program built with CvilleBioHub, VEDP, and UVA, placing four undergraduate interns across chemistry lab, AI workflow, and business strategy roles. The dual-track structure, pairing bench science interns with operations and AI-focused ones, reflects a broader Virginia push to build both the scientific and business talent pipeline the state’s growing biotech sector needs. Read More >
BioBuzz’s Career Catalyst is Back
BioBuzz’s weekly virtual Career Catalyst series returned starting last week, every Wednesday at 6 PM, built for students, recent graduates, and early-career professionals looking for a clearer path into life sciences. Hosted by Sneha Saggurthi, each session brings together professionals, recruiters, advocates, and industry leaders to share practical tools, real-world perspectives, and actionable guidance for building a meaningful career in biotechnology and beyond. Register Now >
Who’s hiring?!
Top Employer
Based in Rockville, Maryland, with additional facilities in Frederick, Meso Scale Diagnostics, LLC. (MSD) develops innovative tools that help advance medical research and drug development. Since 1995, MSD has specialized in assays and instruments that allow researchers to measure multiple biomarkers from a single sample, supporting research in areas like inflammation, neurodegeneration, angiogenesis, and bone health.
MSD works with pharmaceutical companies, universities, government organizations, and clinical laboratories around the world. Through its specialized services, the company helps researchers better understand disease, develop new treatments, and explore new possibilities in personalized medicine.
They are currently hiring across 90+ roles across Maryland. Apply Now >
Other employers and available roles we’re paying attention to this week:
- Pharmaceutics International (Hunt Valley, MD) is hiring a Logistics Coordinator III | Apply Now >
- Siemens Healthineers (Washington, DC) is hiring a Project Manager, Construction, Medical Imaging Installs | Apply Now >
- Terumo Medical (Elkton, MD) is hiring a Shared Services Coordinator | Apply Now >
- AstraZeneca (Gaithersburg, MD) is hiring an Associate Director, Sourcing & Procurement Logistics | Apply Now >
- Curio Wellness (Cockeysville, MD) is hiring a Fulfillment and Vault Supervisor | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across the BioHealth Capital Region.
NIH researchers identify rare antibodies with potential to combat alpha-gal syndrome
NIH researchers have discovered rare antibodies, first identified through malaria research, that block human allergic antibodies from binding to red meat allergens linked to alpha-gal syndrome, a growing tick-bite-associated condition with no current treatment. The findings, published in the Journal of Clinical Investigation, mark an early but promising step toward developing targeted interventions for a condition with roughly 110,000 suspected U.S. cases since 2010. Read More >
FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats
The FDA has issued an Emergency Use Authorization allowing Capstar and its generic Nitenpyram Tablets to be used for both prevention and treatment of New World screwworm infestations in dogs and cats, closing a gap where only treatment options previously existed. Pets weighing at least two pounds and four weeks or older that live in or travel to affected regions should be closely monitored for infestation, with immediate veterinary care recommended if symptoms appear. Read More >
Ecosystem
The partnerships, programs, and policy moves building the BioHealth Capital Region’s life sciences infrastructure — and the organizations driving it forward.
Regulatory Expectations Are Changing: 5 Issues Biopharma Leaders Are Grappling With in 2026
This deep dive breaks down five regulatory pressure points reshaping how biopharma quality teams operate in 2026, from AI’s growing presence on both sides of FDA inspections to workforce capability being treated as an enterprise risk, not just a hiring problem. It also digs into why “human error” is losing ground as a defensible root cause, and how networked manufacturing and effectiveness checks are drawing sharper regulatory scrutiny. Read More >
ARPA-H selects teams to make made-to-order genetic medicine manufacturing possible
ARPA-H has committed up to $125 million across five teams for its GIVE program, aiming to build an automated, distributed biomanufacturing network that produces individualized, RNA-based genetic medicines on demand rather than through today’s slow, centralized model. Four teams are building end-to-end manufacturing platforms while a fifth, the University of Utah, focuses on rapid quality control testing, with the FDA co-developing the regulatory framework to support distributed manufacturing as the technology matures. Read More >
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug
Washington, D.C.-based Vanda Pharmaceuticals has secured European Commission Orphan Designation for imsidolimab in Generalized Pustular Psoriasis, the first orphan status granted to any GPP treatment in the EU. The designation, Vanda’s third after the U.S. and Japan, unlocks protocol assistance and market exclusivity in Europe as the drug’s FDA review continues toward a December 12, 2026 target action date. Read More >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in DMV biotech and life sciences this week.
Maryland Has Grit: Tammi Thomas on TEDCO’s Role in Moving Innovation to Market
On this episode of BioTalk with Rich Bendis, TEDCO President Tammi Thomas explains how the organization has evolved from an early-stage funder into a broader partner for Maryland startups, offering capital, federal funding navigation, and ecosystem connections. Thomas also lays out what makes Maryland’s innovation ecosystem distinct, and where the state’s next opportunity lies: stitching together its existing programs into a more seamless path for founders. Listen Now >
Lab Setup Checklist for Academic Labs on a Tight Budget- Bane Bio
Frederick-based BaneBio breaks down how new lab managers can build out a research space without overspending, from prioritizing must-have equipment against nice-to-haves to deciding when buying pre-owned instruments makes more sense than new. The guide covers safety essentials, big-ticket equipment strategy, and budget-stretching tactics like trade credit and shared core facilities. Read More >
AI Readiness Assessment for Life Sciences
Navitas Life Sciences has released an AI Readiness Assessment exploring why many AI initiatives in pharma stall out before reaching real business value, pointing to gaps in data, governance, and operating models rather than technology choice. With AI investment in life sciences expected to top $15 billion by 2030, the assessment offers a framework for moving from experimentation to scalable, responsible implementation. Download Now >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across the BioHealth Capital Region’s life sciences ecosystem that you don’t want to miss.
2026 Technology Showcase
Wednesday, September 9 • 11:30 AM – 4:30 PM • Frederick, MD
Hosted by Frederick National Laboratory for Cancer Research | Register Now >
Next Generation Sequencing (NGS) Introduction
Tuesday–Thursday, September 9–11 • 9 AM – 5 PM • Germantown, MD
Hosted by Bio-Trac® | Register Now >
Fall in Love with Biotech
Thursday, September 10 • 12 – 3 PM • Richmond, VA
Hosted by VA Bio+Tech Park | Register Now >
Introduction to Upstream Processing
Wednesday–Thursday, September 9–10 • 10 AM – 5 PM • Rockville, MD
Hosted by BioHub Maryland (Maryland Tech Council) | Register Now >
Did we miss something!? Drop us a line →
Stay connected to BioHealth Capital Region life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the BioHealth Capital Region Roundup every Friday.
The week’s most important life sciences news from BioHealth Capital Region— delivered to your inbox.
